CN114395596A - Preparation method and application of soybean, coffee and ganoderma lucidum bioactive peptide - Google Patents
Preparation method and application of soybean, coffee and ganoderma lucidum bioactive peptide Download PDFInfo
- Publication number
- CN114395596A CN114395596A CN202111551229.0A CN202111551229A CN114395596A CN 114395596 A CN114395596 A CN 114395596A CN 202111551229 A CN202111551229 A CN 202111551229A CN 114395596 A CN114395596 A CN 114395596A
- Authority
- CN
- China
- Prior art keywords
- coffee
- soybean
- ganoderma lucidum
- ganoderma
- bioactive peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000068988 Glycine max Species 0.000 title claims abstract description 53
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 53
- 240000007154 Coffea arabica Species 0.000 title claims abstract description 51
- 235000016213 coffee Nutrition 0.000 title claims abstract description 51
- 235000013353 coffee beverage Nutrition 0.000 title claims abstract description 51
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 51
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 30
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 30
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 241000222336 Ganoderma Species 0.000 claims abstract description 24
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 12
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 229940088598 enzyme Drugs 0.000 claims abstract description 11
- 230000000415 inactivating effect Effects 0.000 claims abstract description 8
- 230000036541 health Effects 0.000 claims abstract description 6
- 108090000526 Papain Proteins 0.000 claims abstract description 5
- 102000057297 Pepsin A Human genes 0.000 claims abstract description 5
- 108090000284 Pepsin A Proteins 0.000 claims abstract description 5
- 239000004365 Protease Substances 0.000 claims abstract description 5
- 102000004142 Trypsin Human genes 0.000 claims abstract description 5
- 108090000631 Trypsin Proteins 0.000 claims abstract description 5
- 239000012670 alkaline solution Substances 0.000 claims abstract description 5
- 229940055729 papain Drugs 0.000 claims abstract description 5
- 235000019834 papain Nutrition 0.000 claims abstract description 5
- 229940111202 pepsin Drugs 0.000 claims abstract description 5
- 239000012588 trypsin Substances 0.000 claims abstract description 5
- 239000004382 Amylase Substances 0.000 claims abstract description 3
- 102000013142 Amylases Human genes 0.000 claims abstract description 3
- 108010065511 Amylases Proteins 0.000 claims abstract description 3
- 240000003183 Manihot esculenta Species 0.000 claims abstract description 3
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims abstract description 3
- 235000019418 amylase Nutrition 0.000 claims abstract description 3
- 239000012460 protein solution Substances 0.000 claims abstract description 3
- 229960001322 trypsin Drugs 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000002131 composite material Substances 0.000 claims description 13
- 241000196324 Embryophyta Species 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008213 purified water Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 239000002537 cosmetic Substances 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 239000012535 impurity Substances 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 7
- 238000005728 strengthening Methods 0.000 abstract description 4
- 230000032683 aging Effects 0.000 abstract description 3
- 230000036772 blood pressure Effects 0.000 abstract description 3
- 206010002660 Anoxia Diseases 0.000 abstract description 2
- 241000976983 Anoxia Species 0.000 abstract description 2
- 206010011224 Cough Diseases 0.000 abstract description 2
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 2
- 206010021143 Hypoxia Diseases 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract description 2
- 208000026935 allergic disease Diseases 0.000 abstract description 2
- 230000007815 allergy Effects 0.000 abstract description 2
- 230000000202 analgesic effect Effects 0.000 abstract description 2
- 230000007953 anoxia Effects 0.000 abstract description 2
- 208000006673 asthma Diseases 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000009545 invasion Effects 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 230000003647 oxidation Effects 0.000 abstract description 2
- 238000007254 oxidation reaction Methods 0.000 abstract description 2
- 244000052769 pathogen Species 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 230000005855 radiation Effects 0.000 abstract description 2
- 230000003860 sleep quality Effects 0.000 abstract description 2
- 210000000952 spleen Anatomy 0.000 abstract description 2
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 230000002936 tranquilizing effect Effects 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 150000002333 glycines Chemical class 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 13
- 235000013373 food additive Nutrition 0.000 description 12
- 239000002778 food additive Substances 0.000 description 12
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 9
- 229930091371 Fructose Natural products 0.000 description 9
- 229960002737 fructose Drugs 0.000 description 9
- 239000005715 Fructose Substances 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 229940080701 chymosin Drugs 0.000 description 6
- 108010007119 flavourzyme Proteins 0.000 description 6
- 239000000463 material Substances 0.000 description 5
- 108090000145 Bacillolysin Proteins 0.000 description 4
- 235000005976 Citrus sinensis Nutrition 0.000 description 4
- 240000002319 Citrus sinensis Species 0.000 description 4
- 108091005507 Neutral proteases Proteins 0.000 description 4
- 102000035092 Neutral proteases Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 229930189775 mogroside Natural products 0.000 description 4
- 229940013618 stevioside Drugs 0.000 description 4
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 4
- 235000019202 steviosides Nutrition 0.000 description 4
- 239000012528 membrane Substances 0.000 description 3
- 108091005658 Basic proteases Proteins 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 108010016626 Dipeptides Proteins 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 244000148687 Glycosmis pentaphylla Species 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Endocrinology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Anesthesiology (AREA)
Abstract
A preparation method and application of soybean, coffee and ganoderma lucidum bioactive peptide are disclosed, wherein the raw materials comprise soybean, ganoderma lucidum and coffee, and the specific method comprises the following steps: mixing semen glycines 30-50 parts, Ganoderma 5-15 parts, and coffee 15-40 parts. Firstly, preparing a separated alkaline protein solution, separating soybean, lucid ganoderma and coffee, adding pepsin, trypsin, papain and cassava amylase into the alkaline solution, and inactivating enzymes after enzymolysis. The invention has the effects of replenishing qi and blood, calming the heart, strengthening the spleen and stomach, reducing blood sugar, resisting anoxia, eliminating free radicals, relieving cough, eliminating phlegm, relieving asthma, reducing blood pressure, reducing blood fat and strengthening heart; meanwhile, the health care tea can condition the human body, maintain the balance and stability of the human body function, enhance the immunity of the human body, resist allergy, resist oxidation and delay aging; resisting pathogen invasion, and reducing disease occurrence. Has tranquilizing, and analgesic effects on nervous system, and can improve sleep quality; improving radiation resistance. The health wine has effects of tonifying and nourishing five internal organs, and protecting liver.
Description
Technical Field
The invention relates to the field of preparation of soybean, coffee and ganoderma lucidum bioactive peptides, in particular to a preparation method and application of a soybean, coffee and ganoderma lucidum bioactive peptide.
Background
Bioactive Peptides (BAP) are a generic term for various Peptides ranging from dipeptides to complex linear, cyclic structures, composed of 20 natural amino acids in different compositions and arrangements in proteins, and are multifunctional compounds derived from proteins. The bioactive peptide has various human metabolism and physiological regulation functions, is easy to digest and absorb, has the effects of promoting immunity, hormone regulation, antibiosis, antivirus, blood pressure reduction, blood fat reduction and the like, and is a functional factor with the hottest research topic and great development prospect in the international food industry at present.
The existing bioactive peptide types do not take soybeans, lucid ganoderma and coffee as raw materials, so that the bioactive peptide types are not rich enough, the nutritional ingredients are not diverse enough, and the requirements of consumers cannot be met.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a preparation method and application of a soybean, coffee and ganoderma lucidum bioactive peptide.
In order to achieve the aim of the invention, the invention adopts the specific scheme that:
a method for preparing soybean, coffee and lucid ganoderma bioactive peptides comprises the following steps: mixing 30-50 parts of soybean, 5-15 parts of ganoderma lucidum and 15-40 parts of coffee in proportion, firstly preparing and separating alkaline protein solution, separating the soybean, the ganoderma lucidum and the coffee, adding pepsin, trypsin, papain and cassava amylase into the alkaline solution, and inactivating enzyme after enzymolysis.
Further, the protein raw materials of the soybeans, the lucid ganoderma and the coffee are prepared by enzymolysis of pepsin and trypsin.
Further, the soybean, ganoderma lucidum and coffee protein raw materials are prepared by papain or compound enzyme Protamex enzymolysis.
Further, the mass ratio of the soybean, ganoderma, kaempferide to the alpha-enkephalin is (1.3-3.1): (1.3-2.2): (1.8-4.1).
Further, the mass ratio of the soybean ganoderma lucidum coffee compound peptide is (1.3-4.0): 0.42.
further, removing surface impurities from the composite micromolecular ionic peptide liquid, centrifuging to obtain supernatant, and thus obtaining the composite soybean ganoderma lucidum coffee micromolecular (ionic) peptide.
An application of soybean, coffee and ganoderma bioactive peptide in preparing cosmetics, food, medicine and health-care food is prepared from soybean, coffee and ganoderma through proportional mixing with purified water (1-5%), adding flavouring, plant antiseptic and purified water, and preparing food, medicine and health-care food.
The invention has the beneficial effects that:
the invention prepares the composite plant micromolecule soybean coffee ganoderma lucidum peptide liquid in a specific molecular weight region by a specific process. The three or four components are combined in a proper proportion, and can achieve the effects of replenishing qi and blood, calming the heart, strengthening the spleen and stomach, reducing blood sugar, resisting anoxia, eliminating free radicals, relieving cough, eliminating phlegm, relieving asthma, reducing blood pressure, reducing blood fat and strengthening heart with less use amount. Meanwhile, the health care tea has the effects of conditioning the body, maintaining the balance and stability of the human body function, improving the decline of the immune function caused by aging, enhancing the autoimmunity, resisting allergy, resisting oxidation and delaying aging. Resisting pathogen invasion, and reducing disease occurrence. Has tranquilizing, analgesic, and sleep quality improving effects. Improving sub-health for sub-health people, getting rid of sub-health state, and improving radiation resistance. The health wine has effects of tonifying and nourishing five internal organs, and protecting liver.
Detailed Description
The present invention is further described below by way of specific examples, but the present invention is not limited to only the following examples. Variations, combinations, or substitutions of the invention, which are within the scope of the invention or the spirit, scope of the invention, will be apparent to those of skill in the art and are within the scope of the invention.
A process for preparing the bioactive peptide of soybean, coffee and ganoderma includes such steps as preparing the alkaline solution of protein, separating by mixing soybean, coffee and ganoderma in 30-70 portions, 5-15 portions and 15-40 portions. Adding Alcalase protease into the alkaline solution obtained by separating soybean, coffee and ganoderma lucidum, performing enzymolysis, inactivating enzyme, centrifuging, and collecting supernatant, i.e. the compound soybean coffee ganoderma lucidum peptide solution. Carrying out reflux ultrafiltration on the soybean, lucid ganoderma, caffeine and enkephalin liquid in a greenhouse, and carrying out adsorption deodorization on activated carbon at the same time of the ultrafiltration. And performing series connection on 9 ultrafiltration membranes in the ultrafiltration operation to intercept molecular weight of 2500 Da-4500 Da and pressure of 0.2 Mpa-1.2 Mpa, treating for 5-20 min, removing inorganic salt ions with relative molecular mass less than or equal to 2500Da, and collecting and filtering the soybean, coffee and lucid ganoderma compound peptide liquid. And adding flavoring agents such as orange and strawberry liquid, fructo-oligosaccharide, xylitol, fruit sugar and the like in a greenhouse to improve the taste of the finished product of the compound peptide liquid. The oral liquid with health care and treatment functions is produced.
Example 1
The raw materials comprise the following components in parts by weight: 80 parts of compound soybean, lucid ganoderma and coffee compound peptide, 2 parts of crystalline fructose and 2 parts of food additive.
The food additive is prepared by mixing the following raw materials in parts by weight: 0.5 part of sweet orange essence, 0.5 part of bitter taste reducing essence, 0.4 part of mogroside and 0.05 part of stevioside.
A preparation method of plant peptide comprises the following steps:
s1, dissolving the composite soybean ganoderma coffee peptide in water (the mass ratio of materials to water is 1:10), adjusting the pH of the solution to 8.5 by using 1mol/L NaOH solution, adding alkaline protease for enzymolysis, then adjusting the pH to 7 by using 1mol/L HC1 solution, adding neutral protease for enzymolysis, adding 2500U/kg of the neutral protease for enzymolysis, inactivating the enzyme after the enzymolysis is finished, centrifuging, taking supernate, and performing ultrafiltration by using an ultrafiltration membrane with the molecular weight cutoff of 1000U to obtain filtrate with the molecular weight of less than 1000U, thereby obtaining the soybean ganoderma coffee composite oligopeptide concentrated solution.
S2, mixing soybean, lucid ganoderma and coffee oligopeptides, dissolving the soybean, lucid ganoderma and coffee oligopeptides in water (the mass ratio of the materials to the water is 1:10), adjusting the pH to 7 by using 1mol/L HC1 solution, adding a-chymosin and flavourzyme for reaction, wherein the addition amount of the a-chymosin is 2000U/kg, the addition amount of the flavourzyme is 3000U/kg, inactivating enzymes after the reaction is finished, centrifuging, taking supernate, dialyzing, precooling for 50min at the temperature of-10 ℃ to obtain a composite peptide concentrated solution, adding crystalline fructose and a food additive, and dissolving and mixing uniformly to obtain the plant peptide oral liquid.
Example 2
The raw materials comprise the following components in parts by weight: 75 parts of soybean ganoderma lucidum coffee composite peptide, 15 parts of crystalline fructose and 1.5 parts of food additive.
The food additive is prepared by mixing the following raw materials in parts by weight: 0.5 part of sweet orange essence, 0.5 part of bitter taste reducing essence, 0.4 part of mogroside and 0.05 part of stevioside.
A preparation method of plant peptide comprises the following steps:
s1, dissolving soybean ganoderma coffee peptide in water (the mass ratio of materials to water is 1:10), adjusting the pH of the solution to 8.5 by using 1mol/L NaOH solution, adding alkaline protease for enzymolysis, then adjusting the pH to 7 by using 1mol/L HC1 solution, adding neutral protease for enzymolysis, adding 2500U/kg of the neutral protease for enzymolysis, killing enzyme after the enzymolysis is finished, centrifuging, taking supernate, and performing ultrafiltration by using an ultrafiltration membrane with the molecular weight cutoff of 1000U to obtain filtrate with the molecular weight of less than 1000U, thereby obtaining the soybean ganoderma coffee composite oligomeric liquid.
S2, mixing and dissolving soybean ganoderma coffee oligopeptides in water (the mass ratio of the materials to the water is 1:10), adjusting the pH to 6 by using 1mol/L HC1 solution, adding a-chymosin and flavourzyme for reaction, wherein the addition amount of the a-chymosin is 2000U/kg, the addition amount of the flavourzyme is 3000U/kg, inactivating enzyme after the reaction is finished, centrifuging, taking supernate to obtain a compound peptide concentrated solution, adding crystalline fructose and a food additive, and dissolving and mixing uniformly to obtain the plant peptide oral liquid.
Comparative example 1
The raw materials comprise the following components in parts by weight: 75 parts of soybean ganoderma lucidum coffee composite peptide, 15 parts of crystalline fructose and 1.5 parts of food additive.
The food additive is prepared by mixing the following raw materials in parts by weight: 0.5 part of sweet orange essence, 0.5 part of bitter taste reducing essence, 0.4 part of mogroside and 0.05 part of stevioside.
A preparation method of plant peptide comprises the following steps:
adding crystalline fructose and food additive into the soybean-ganoderma-coffee composite peptide, dissolving and mixing uniformly to obtain the plant peptide oral liquid.
Comparative example 2
The raw materials comprise the following components in parts by weight: 75 parts of soybean ganoderma lucidum coffee composite peptide, 15 parts of crystalline fructose and 1.5 parts of food additive.
The food additive is prepared by mixing the following raw materials in parts by weight: 0.5 part of sweet orange essence, 0.5 part of bitter taste reducing essence, 0.4 part of mogroside and 0.05 part of stevioside.
A preparation method of plant peptide comprises the following steps:
mixing and dissolving soybean ganoderma lucidum coffee peptides in water (the mass ratio of the materials to the water is 1:10), adjusting the pH to 6 by using 1mol/L HC1 solution, adding a-chymosin and flavourzyme for reaction, wherein the addition amount of the a-chymosin is 2000U/kg, the addition amount of the flavourzyme is 3000U/kg, inactivating enzyme after the reaction is finished, centrifuging, taking supernate, adding crystalline fructose and food additives, and dissolving and mixing uniformly to prepare the plant peptide liquid oral liquid.
The above description is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the present invention, and any modifications, equivalents and improvements made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (7)
1. A preparation method of soybean, coffee and lucid ganoderma bioactive peptides is characterized in that raw materials comprise soybeans, lucid ganoderma and coffee, and the specific method comprises the following steps: mixing 30-50 parts of soybean, 5-15 parts of ganoderma lucidum and 15-40 parts of coffee in proportion, firstly preparing and separating alkaline protein solution, separating the soybean, the ganoderma lucidum and the coffee, adding pepsin, trypsin, papain and cassava amylase into the alkaline solution, and inactivating enzyme after enzymolysis.
2. The method for preparing soybean coffee ganoderma lucidum bioactive peptide according to claim 1, wherein the method comprises the following steps: the protein raw materials of the soybean, the lucid ganoderma and the coffee are prepared by enzymolysis of pepsin and trypsin.
3. The method for preparing soybean coffee ganoderma lucidum bioactive peptide according to claim 1, wherein the method comprises the following steps: the soybean, ganoderma lucidum and coffee protein raw materials are prepared by papain or compound enzyme Protamex enzymolysis.
4. The method for preparing the bioactive peptide of the soybean, the coffee and the ganoderma lucidum as claimed in any one of claims 1 to 3, wherein the bioactive peptide comprises the following components in percentage by weight: the weight ratio of the soybean, ganoderma, kaempferide to the alpha-enkephalin is (1.3-3.1): (1.3-2.2): (1.8-4.1).
5. The method for preparing the bioactive peptide of the soybean, the coffee and the ganoderma lucidum as claimed in any one of claims 1 to 3, wherein the bioactive peptide comprises the following components in percentage by weight: the mass ratio of the soybean ganoderma lucidum coffee compound peptide is (1.3-4.0): 0.42.
6. the method for preparing soybean coffee ganoderma lucidum bioactive peptide according to claim 1, wherein the method comprises the following steps: removing surface impurities from the composite micromolecular ionic peptide liquid, and centrifuging to obtain supernatant, namely the composite soybean ganoderma lucidum coffee micromolecular (ionic) peptide.
7. The application of the soybean, coffee and ganoderma lucidum bioactive peptide is characterized in that: blending with purified water according to the proportion of 1-5%, adding flavoring agent, plant preservative and purified water to obtain raw materials, and making into cosmetics, foods or medicines and health products.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111551229.0A CN114395596A (en) | 2021-12-17 | 2021-12-17 | Preparation method and application of soybean, coffee and ganoderma lucidum bioactive peptide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111551229.0A CN114395596A (en) | 2021-12-17 | 2021-12-17 | Preparation method and application of soybean, coffee and ganoderma lucidum bioactive peptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114395596A true CN114395596A (en) | 2022-04-26 |
Family
ID=81226905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111551229.0A Pending CN114395596A (en) | 2021-12-17 | 2021-12-17 | Preparation method and application of soybean, coffee and ganoderma lucidum bioactive peptide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114395596A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1489923A (en) * | 2003-09-16 | 2004-04-21 | 北京陶正生物工程技术有限公司 | Method for producing soya protein bioactive peptide |
| CN104431208A (en) * | 2014-12-29 | 2015-03-25 | 陕西天宝大豆食品技术研究所 | Peptide coffee and preparation method thereof |
| CN110037163A (en) * | 2019-04-24 | 2019-07-23 | 王书敏 | A kind of preparation method of compound plant protein peptide |
| CN111358009A (en) * | 2020-03-16 | 2020-07-03 | 赵秋萍 | Plant peptide and preparation method and application thereof |
| CN111662946A (en) * | 2020-07-17 | 2020-09-15 | 上海应用技术大学 | Method for preparing oligopeptide by enzymolysis of ganoderma lucidum water-soluble protein |
-
2021
- 2021-12-17 CN CN202111551229.0A patent/CN114395596A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1489923A (en) * | 2003-09-16 | 2004-04-21 | 北京陶正生物工程技术有限公司 | Method for producing soya protein bioactive peptide |
| CN104431208A (en) * | 2014-12-29 | 2015-03-25 | 陕西天宝大豆食品技术研究所 | Peptide coffee and preparation method thereof |
| CN110037163A (en) * | 2019-04-24 | 2019-07-23 | 王书敏 | A kind of preparation method of compound plant protein peptide |
| CN111358009A (en) * | 2020-03-16 | 2020-07-03 | 赵秋萍 | Plant peptide and preparation method and application thereof |
| CN111662946A (en) * | 2020-07-17 | 2020-09-15 | 上海应用技术大学 | Method for preparing oligopeptide by enzymolysis of ganoderma lucidum water-soluble protein |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103689733B (en) | Preparation method of soybean peptide local flavor beverage | |
| US20220024974A1 (en) | Methods for producing a rice protein peptide and applications thereof | |
| CN105614899B (en) | A kind of low molecule soybean peptide and preparation method thereof | |
| CN103689732B (en) | Soybean peptide local flavor beverage | |
| CN111642666A (en) | Preparation method of ginseng extract soybean peptide powder solid beverage | |
| CN110205353A (en) | A kind of saline taste enhancing peptide and its preparation method and application | |
| CN101238904B (en) | Chickpea bean sprout juice tea and preparation method and application | |
| CN108220374A (en) | The preparation method of Soybean Peptide | |
| CN108546281A (en) | A kind of ginseng oligopeptide and its preparation method and application | |
| CN111772194A (en) | Food formula for tonifying qi, soothing nerves, replenishing vital essence and reinforcing kidney | |
| CN111938062A (en) | Oyster protein solid beverage rich in biological zinc and preparation method thereof | |
| CN1377590A (en) | Method for producing soybean protein hydrolyate and use | |
| CN110499351A (en) | A kind of soybean peptide and the preparation method and application thereof with high ACE inhibitory activity | |
| CN114395596A (en) | Preparation method and application of soybean, coffee and ganoderma lucidum bioactive peptide | |
| CN111329988A (en) | Donkey-hide gelatin peptide buccal tablet rich in free arginine and preparation method thereof | |
| CN101130801A (en) | Preparation of active antihypertensive peptide product | |
| CN110810852A (en) | Preparation method of earthworm freeze-dried powder for regulating cardiovascular function | |
| CN104757655A (en) | Earthworm amino acid beverage and preparation method thereof | |
| CN114480539A (en) | Preparation method and application of soybean, coffee and ginseng bioactive peptides | |
| CN114517219A (en) | Preparation method and application of soybean, coffee and gastrodia elata bioactive peptide | |
| CN114480540A (en) | Preparation method and application of soybean, coffee and hawthorn bioactive peptide | |
| CN114214380A (en) | Preparation method and application of soybean, coffee and American ginseng bioactive peptides | |
| CN114480536A (en) | Preparation method and application of soybean, coffee and sealwort bioactive peptide | |
| CN114717284A (en) | Preparation method and application of soybean, coffee and cordyceps flower bioactive peptide | |
| CN114438155A (en) | Preparation method and application of soybean, coffee and Chinese wolfberry bioactive peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220426 |
|
| RJ01 | Rejection of invention patent application after publication |